Alnylam and collaborators to present apollo phase 3 study results at 1st
european attr amyloidosis meeting for patients and doctors
Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq:alny), the leading rnai therapeutics company, announced today that the results of the apollo phase 3 study of patisiran in hereditary attr (hattr) amyloidosis patients with polyneuropathy, as well as additional posters on patisiran and hattr amyloidosis, will be presented at the 1st european attr amyloidosis meeting for patients and doctors being held november 2-3, 2017 in paris, france. presentations include: patisiran, an investigational rnai therapeutic for patients with hereditary transthyretin-mediated (hattr) amyloidosis with polyneuropathy: results from the phase 3 apollo studyauthors: d adams, a gonzalez-duarte, w o'riordan, cc yang, t yamashita, a kristen, i tournev, h schmidt, t coelho, jl berk, kp lin, pj dyck, p gandhi, m sweetser, j chen, j gollob, o suhrpresentation type: oraldate/time: november 2, 2017, 3:35 pm cet long-term, open-label clinical experience with patisiran, an investigational rnai therapeutic for patients with hereditary transthyretin-mediated (hattr) amyloidosis with polyneuropathyauthors: jl berk, d adams, o suhr, i conceicao, m waddington cruz, h schmidt, j buades, j campistol, j pouget, m polydefkis, am partisano, m sweetser, j chen, j gollob, t coelhopresentation type: posterdate: november 2-3, 2017 reasons for discontinuation of ttr stabilizers and/or ttr fibril disrupter: an analysis of baseline demographics of patients with hattr amyloidosis in the phase 3 apollo studyauthors: h schmidt, w o’riordan, t yamashita, jl berk, i tournev, m mezei, v plante-bordeneuve, y sekijima, ob suhr, g vita, am partisano, j gollob, d adamspresentation type: posterdate: november 2-3, 2017 characteristics of patients with hereditary transthyretin-mediated amyloidosis on the us liver transplant waiting listauthors: d brandman, sa ŽivkoviĆ, w irish, lm gache, a mcmanus, j gollob, am partisano, s agarwalpresentation type: posterdate: november 2-3, 2017 alnylam management will discuss these results via conference call on thursday, november 2, 2017, at 12:30 p.m. et. a slide presentation will also be available on the investors page of the company’s website, www.alnylam.com, to accompany the conference call. to access the call, please dial 877-312-7507 (domestic) or 631-813-4828 (international) five minutes prior to the start time and refer to conference id 2354344. a replay of the call will be available beginning at 3:30 p.m. et on the day of the call. to access the replay, please dial (855) 859-2056 (domestic) or (404) 537-3406 (international), and refer to conference id 2354344. about alnylam pharmaceuticals alnylam (nasdaq: alny) is leading the translation of rna interference (rnai) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, and hepatic infectious diseases. based on nobel prize-winning science, rnai therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. founded in 2002, alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust discovery platform and deep pipeline of investigational medicines, including four product candidates that are in late-stage development. looking forward, alnylam will continue to execute on its "alnylam 2020" strategy of building a multi-product, commercial-stage biopharmaceutical company with a sustainable pipeline of rnai-based medicines to address the needs of patients who have limited or inadequate treatment options. alnylam employs over 600 people in the u.s. and europe and is headquartered in cambridge, ma. for more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on twitter at @alnylam or on linkedin.
